The idea of rejuvenating aging cells by "resetting" them is moving from the realm of science fiction into real medicine. The American biotechnology company Life Biosciences has received approval to conduct clinical trials of its ER-100 drug, which is based on partial epigenetic reprogramming of cells. This marks the first time a technology capable of returning cells to a more youthful state will be tested in humans.

Mechanisms of Aging and Epigenetics

Aging has traditionally been viewed as an inevitable process that leads to declining organ function and the development of chronic diseases. However, modern research shows that not only DNA damage but also epigenetic changes—alterations in the system that turns genes on and off—play a key role in this process. Over time, these changes accumulate, disrupting cell function and reducing their ability to repair themselves.

The Discovery of Yamanaka Factors

In 2006, it was discovered that four genes—Oct4, Sox2, Klf4, and c-Myc (OSKM)—can reprogram mature cells, returning them to a state similar to embryonic cells. Later, it was found that activating only some of these factors and controlling their expression can rejuvenate a cell without turning it into a stem cell. This approach is known as epigenetic reprogramming. However, the use of c-Myc is associated with an increased risk of cancer, so modern studies use only the OSK combination.

Animal Experiments

In 2020, researchers at Harvard Medical School demonstrated that expressing OSK factors in the retinal neurons of mice could restore youthful epigenetic patterns. As a result, damaged axons in rodents regenerated, and their vision improved. This became one of the first pieces of evidence that adult mammalian tissues can retain a "memory" of a youthful state and return to it.

Development and Essence of ER-100 Therapy

Based on these findings, the ER-100 gene therapy was developed to deliver instructions for temporary activation of OSK factors into retinal cells. Unlike full reprogramming, which turns cells into stem cells, the partial approach is intended only to restore epigenetic settings, returning the cell to a more youthful state.

Previous Research and Future Prospects

Similar experiments have previously been conducted on mice, primates, and laboratory models. Some companies planned to use this method to combat age-related changes in animals before eventually testing it in humans. However, Life Biosciences was the first to receive approval for clinical trials. On February 2, 2026, the company announced that the U.S. FDA had authorized the first clinical trials for treating retinal diseases in humans. These diseases are associated with the loss of ganglion cells—neurons that transmit visual information from the eye to the brain. Such cells are almost incapable of regeneration, and their damage usually leads to blindness.

The Importance of Clinical Trials

If partial reprogramming technology can restore the function of these cells, it could be a significant step forward in treating glaucoma and other neurodegenerative eye diseases. Early animal experiments have already shown impressive results: activation of OSK factors led to the restoration of a more youthful epigenetic age in cells. This suggests that aging may not only be the result of irreversible damage but also a consequence of disruptions in the epigenetic program, which, in theory, can be restored.

Safety and Next Steps

The first clinical trials of ER-100 will primarily focus on evaluating the safety of the therapy, as the method itself carries a risk of developing cancer. If the results are successful, the technology could pave the way for a new class of drugs that not only alleviate disease symptoms but also restore the youthful state of cells and tissues.

The Future of Epigenetic Rejuvenation

Although a true "anti-aging drug" is still a long way off, the start of human trials shows that the ideas of epigenetic rejuvenation are gradually moving beyond the laboratory and becoming part of real clinical practice.